Corticosteroid-Related Glaucoma: A Preventable Cause of Blindness

[1]Velram R, [2]Lalitha R, [3]Kasthuri K, [4]Hariharan G

[1]Assistant Professor, Ophthalmology, Meenakshi Medical College Hospital and Research Institute, Enathur, Kanchipuram

[2]Associate Professor, Anatomy, Meenakshi Medical College Hospital and Research Institute, Enathur, Kanchipuram

[3]Associate Professor, Bio Chemistry, Meenakshi Medical College Hospital and Research Institute, Enathur, Kanchipuram

[4] Assistant Professor, Community Medicine Meenakshi Medical College Hospital and Research Institute, Enathur, Kanchipuram

Corresponding Author: Anitha S, Assistant Professor, Microbiology, Meenakshi Medical College Hospital and Research Institute, Enathur, Kanchipuram

ABSTRACT

The use of viable steroid eye drops is something that clinical consideration professionals educate on a regular basis in order to manage and control postoperative disturbances that occur after phacoemulsification. It is crucial to be aware of the potential adverse effects that may be brought about by the usage of steroids, even if there are several benefits linked to their application. Patients who respond to steroids may experience a rise in intraocular pressure (IOP) as a result of using strong steroid drops. About a month after the first eye drop medication has been started, the decline in intraocular pressure (IOP) that results from the negative effects of steroids usually becomes apparent. The history of steroid-induced glaucoma may be traced (SIG) all the way back to the 1950s, when it was first documented that major adrenocorticotropic hormone synthetic substances were associated with the disease. The increase in intraocular pressure (IOP) is a multifaceted issue that is influenced by a number of different components; nevertheless, the most important component is the extended check that is performed within the flood instruments of the trabecular meshwork. When it comes to the various risk factors that are related with visual hypertension that can be achieved through the use of steroids, the most common one is an earlier onset of glaucoma. There has been a correlation shown between the usage of various courses of steroids and the occurrence of ocular hypertension. The continuous organization strategy focuses on the evaluation of decisions on steroid-saving treatment, the cessation of steroid use, the utilization of prescriptions to reduce intraocular pressure, and the consideration of interventional laser and medical procedures..

Keywords: consideration, phacoemulsification, intraocular.

INTRODUCTION

1. As a result of the widespread usage of steroids as a treatment option for immune system disorders that are not caused by fire, medical experts regularly utilize steroids to treat a variety of illnesses**.** recommend them to their patients.
2. The employment of efficient steroid eye drops is something that medical care professionals routinely recommend in order to monitor and manage postoperative irritation that occurs after phacoemulsification.
3. As a consequence of this, the use of steroids that are effective ultimately results in an increase in intraocular pressure (IOP). If you have chronic visual hypertension for a lengthy period of time, you may be at an increased risk of developing steroid-induced glaucoma. This is because persistent hypertension can cause damage to the optic nerve. It is because the

disease has an effect on the visual nerve that this is the case.

4. The oldest occurrence of steroid-induced glaucoma (SIG) that has been documented dates back to the 1950s, which coincides with the introduction of key adrenocorticotropic drugs on the market for pharmaceuticals.
5. Following an evaluation that lasted for four years, Francois presented a comprehensive report on the underlying cause of raised intraocular pressure (IOP) that was brought about by the local application of steroid drops.
6. The researchers were interested in this auxiliary glaucoma because it has the potential to shed light on the intricate mechanisms that contribute to open-angle glaucoma at the same time.
7. An increased resistance in the outflow mechanisms of the trabecular meshwork (TM) is the primary cause of raised intraocular pressure (IOP). This is a complicated issue that is regulated by a number of different factors. It is possible that the application of steroid drops will result in the formation of cross-connections within the network, which will make it easier to incorporate modifications into the structure of the actin fiber chain.
8. An additional possible explanation could be that there is an increase in the levels of collagen and fibronectin within the extracellular matrix of the juxta-canal region, which then leads to an increase in the number of accretions.
9. The use of topical steroids has an effect on the turnover of components and enzymes in the trabecular meshwork, which results in an increase in the outflow resistance within this essential component of the intraocular pressure regulation system.
10. The opportunity to select non-steroidal alternatives instead of utilizing steroids. Regardless of steroid usage, it is crucial to monitor intraocular pressure (IOP) in scenarios where this may not be feasible. Timely intervention is essential when addressing the ocular hypertensive response to avert vision-related complications, especially in children..

ETIOLOGY

It is possible for individuals who have been exposed to steroids to experience ocular hypertension, also known as OHT. In patients with SIG, an elevated intraocular pressure (IOP) can cause irreversible ocular neuropathy. Steroid response has been defined in a number of different ways over the course of history. When determining whether or not an individual has increased intraocular pressure (IOP), it is possible to use many cutoff thresholds. An intraocular pressure (IOP) elevation that is larger than 10 mm Hg over the norm with clinical relevance, an increase in IOP that is greater than 5 mm Hg, an IOP that is higher than 21 or 24 mm Hg, a perceptible rise in IOP that is greater than 5 mm Hg with readings that are higher than 24 mm Hg, or any combination of these factors. The ultimate definition is the one that is accepted by the majority of people.

Steroid responders demonstrate high intraocular pressure (IOP), particularly following the administration of powerful periocular and intraocular steroid therapies. This lends credence to the idea that ophthalmic hypersensitivity reaction (OHT) may occur after the administration of medicines through the intranasal, inhalational, topical, or dermatological routes. Approximately one and a half months after the treatment of steroid eye drops, clinical doctors noticed an increase in the intraocular pressure of the patient. There is a possibility that it took place at a certain intersection in the past. Following the discontinuation of steroid treatment, it is typically anticipated that the intraocular pressure (IOP) will return to its normal level after around fourteen days. As an additional point of interest, it is possible that corticosteroid eye injections could cause a sudden rise in intraocular pressure (IOP). It is possible that the intraocular pressure (IOP) will be affected by the inclusion of optional classes that focus on the link between glucocorticoids.

EPIDEMIOLOGY

Unlike other forms of glaucoma, the particular presentation of optional glaucoma is challenging to ascertain. The average population with GC has a non-response rate of roughly 61 to 63%, leading to intraocular pressure (IOP) levels below 5 mm Hg. Consequently, roughly 33 percent of the population demonstrates a moderate response, marked by an elevation in intraocular pressure (IOP) values between 6 and 15 mm Hg. A subset of four to six percent of patients exhibits intraocular pressure

(IOP) levels over 15 mm Hg. This subset is highly responsive. Conversely, the use of steroid eye drops led to a substantial elevation in intraocular pressure (IOP) in 46 to 92 percent of patients diagnosed with primary open-angle glaucoma (POAG).

The occurrence of steroid reactions in children is similar to that seen in the overall adult population. Moreover, research indicates a higher prevalence of this anomaly in pediatric patients. In comparison to adults, children exhibit an earlier onset of the steroid reaction and demonstrate a more accelerated progression. This leads to an elevation in intraocular pressure (IOP) in certain individuals after merely one day of glucocorticoid administration. Recent findings indicate a rise in the incidence of SIG in youngsters, correlated with the unregulated use of potent steroid eye drops.

Predisposing factors

The specialists have identified a number of aspects that are anticipated to have a role in the enhancement of SIG, despite the fact that their understanding is limited. A couple of the variables that have been recorded are shown in the following paragraphs.

Age

Another element that is considered to be a risk factor is age. Due to the fact that the use of prednisolone drops causes a large increase in intraocular pressure (IOP) in children under the age of ten, these children are at the greatest risk of developing glaucoma. It is estimated that around twenty-five percent of all cases of glaucoma that are developed in children are caused by this particular subtype. In children, the increase in intraocular pressure (IOP) and the potential glaucomatous damage that may occur might begin sooner, demonstrate a more substantial severity upon presentation, and advance at a faster pace than in adults. This is because children are more likely to be exposed to the condition than adults. People who are older than six years old and children younger than six years old are more likely to be affected by the disorder. Older people are more likely to experience an increase in intraocular pressure (IOP) as a consequence of getting steroid eye drops. This is because older people have a higher chance of developing cataracts. It was established that there was a 1.72 percent chance that glaucoma will improve in elderly people who were treated with steroid drops that were effective. The Steroid Treatment for Uveitis across Multiple Centers Individuals under the age of fifty were found as a risk factor related with an increase of 10 mm Hg or more in intravitreal fluocinolone acetonide in the eyes of patients who were diagnosed with uveitis by preliminary specialists. The effect of steroids that are effective is substantially more evident in children than it is in adults who have visual hypertension, and there are a number of reasons that contribute to this differential. It is largely agreed upon that the immature trabecular meshwork is the most convincing of these components.

Other Pre Disposing factors

The concept of an intrinsic susceptibility for corticosteroid glaucoma has been offered by a variety of manufacturers. In accordance with the current composition, patients who are diagnosed with specific connective tissue illnesses, type I diabetes, or moderate astigmatism exhibit a heightened sensitivity to the effects of steroids. There have been a number of consequences that have been documented, including an increase in corneal thickness and a slight development of the students. The existence of a link between these motions and visual hypertension is not supported by any research as of now. Individuals who suffer from conditions such as hide dispersing condition, terrible point slump, or endogenous hypercortisolism are more susceptible to the adverse effects of corticosteroid medications.

ROUTES OF STEROID ADMINISTRATION

Topical route

In the process of monitoring conjunctivitis, response qualities, visual disturbances, and recuperation from laser and surgical procedures, clinical attention providers frequently turn to skin steroids as a therapy option that is compelling. The high rate of SIG in both adolescents and adults can be determined thanks to the presence of steroids that are independent and compelling. Extending the intraocular pressure (IOP) from 6 to 22 mm Hg might continue for a considerable amount of time after medication has been administered. There is a correlation between the use of skin steroid medications and an ongoing increase in intraocular pressure (IOP).It is recommended to use more contemporary skin definitions that have a less significant impact on intraocular pressure. An increase in intraocular pressure (IOP) may persist for a length of time that is as long as 18 months after the cessation of

therapeutic intervention.

Intra ocular route

During the course of the most recent decade, the use of intraocular steroids has significantly increased by a significant margin. There is a connection between this and the employment of intravitreal implantations or additions for the treatment of choroidal, macular, and retinal snare defects. In contrast to dexamethasone, which is related with a lower risk of intravitreal injections, fluocinolone is more frequently connected with SIG. When these medications are used, the risk of developing SIG can increase from 11% to 37%, and when those medications are combined with uveitis, the risk can increase to as high as 79%. Over the course of a month and a half, there is a discernible increase in intraocular pressure (IOP), which reaches its peak at seven months, and then begins to decrease after three to four months. This pattern continues until the end of the month.

The periocular route

Despite the fact that it is located in close proximity to the front chamber point, the sub-join area is the preferred periocular channel in steroid responders. This is because it raises the danger of sudden intraocular pressure (SIG). One study investigated the effects of various periocular corticosteroid therapies on patients suffering with uveitis from a number of distinct perspectives. An increase in intraocular pressure (IOP) that was more than 24 mm Hg was observed in around 35 percent of participants, and 2.4% of those individuals required medical treatment for glaucoma.

The systemic routeA considerable percentage of persistent provoking illnesses are often treated with the injection of fundamental steroids as the conventional course of treatment. The use of fundamental treatment, as opposed to visual treatment, results in a reduction in the risk of SIG happening. It is possible for patients who have delayed foundational steroid treatment to experience a large increase in intraocular pressure (IOP), which may continue for a considerable amount of time. According to the findings of a number of studies, it is assumed that around twenty percent of people who have glaucoma have been administered basic cortisone because of their condition. Every one of these individuals exhibited a decrease in their ability to distinguish between objects visually.

Inhalational route

It has been demonstrated that there is a direct correlation between the use of inhaled steroids and the development of ocular hypertension. The risk is higher in individuals who have a family history of glaucoma, and this is especially true when the dosages and delivery frequency are increased. The intraocular pressure (IOP)-lowering effect was speculated to be caused by either the main absorption of the drug or an inadequate administration approach that may promote the direct entry of the drug into the eye. **DURATION OF STEROID**

During the course of the standard extended durations of steroid treatment, an increase in intraocular pressure (IOP) frequently takes place in individuals who respond to steroids. As a result of the continual association of steroids, the ascent may take place during the span of an hour or may connect over the course of several years. Following the discontinuation of steroid treatment, the normalization of intraocular pressure typically takes place somewhere in the neighborhood of one month has passed.

PATHOPHYSIOLOGY

Numerous investigations have revealed that there is a connection between steroids and increased surge resistance in the strain weak channel. In light of the findings of in-vitro exams, the definitive foundation of the association between changes in TM, elevated intraocular pressure, and steroid openness was not feasible. The analysis of protein measurements revealed that there were significant differences in the levels of specific glycosaminoglycans discovered in eyes that had been treated with steroids in comparison to eyes that served as controls. There are a number of components of the extracellular lattice that have been linked to the decreased porousness of steroid-treated trabecular meshwork. These components include glycosaminoglycans, among others. It has been discovered that steroid openness can lead to deregulation of phagocytosis and autophagy in the trabecular meshwork. This information was obtained through research.

In tissue culture and creature models, researchers have focused their attention on a select few protein-related processes that flag proteins. The cytoskeletal remodeling that occurs in steroid-treated trabecular meshwork is contributed to by the activation of Rho-

related protein kinase (ROCK), and ROCK inhibitors are responsible for switching this rebuilding. The differential articulation of the long-noncoding RNA ANRIL and the quality of p15 has been observed in mice with steroid-actuated glaucoma. This observation has led to the hypothesis that the control of TM cell senescence by ANRIL and p15 contributes to the pathophysiology of this condition. In addition to their role in the pressure-free outpouring of uveoscleral fluid, prostaglandins have the potential to increase TM surge. The process of altering the development factor β (TGFβ) flagging has also been gotten caught up in this.

FEATURES TO LOOK

Patients frequently exhibit aftereffects that are similar to those that are observed in those who have POAG, with the manifestation of these secondary effects shifting in perspective as the patient matures. When it comes to youngsters, the manifestation of natural glaucoma may include symptoms such as prolonged tear production, compressions of the eyelids, and an increased sensitivity to light. Youths are displaying their credits in accordance with the developmental POAG. It is common for adults to exhibit symptoms such as elevated intraocular pressure (IOP), unobstructed focusing during gonioscopy, impaired vision, and measurements of the optic plate. In some cases, the ascent of SIG can be achieved by the connection of steroid eye drops with vernal kerato conjunctivitis (VKC), which is not essentially a predetermined condition.

AN ANALYSIS OF

In the majority of instances, a comprehensive examination of the eye does not disclose anything that will be of particular significance. Because the patient's intraocular pressure (IOP) is continuously greater than the normal range of 10 to 22 mm Hg, it has been concluded that the patient has developed hypertension as a result of their use of steroids. This conclusion was reached based on the patient's history of steroid dosage and administration. When it comes to the diagnosis of SIG, as well as any other type of glaucoma, Tonometry is an extremely important instrument.

By looking over the patient's medical history, we might be able to determine the causes that contributed to the condition. Patients who are suffering from a variety of allergic conjunctivitis may find relief from their symptoms by delaying the use of steroid eye drops. Patients who have undergone surgery, such as a photorefractive keratectomy, may be given steroid eye drops as a prescription, or they may already have these drugs in their supply. Another group of people who are at an elevated risk for glaucoma is those who have received a kidney transplant. The evaluation is dissected into a number of steps, each of which is described in greater detail below.

THE RECORDING OF VISUAL PRECAUTIONS,

1. Following the completion of an inspection of both the front and the back portions,

The subsequent three steps in the technique are as follows

2. Tonometry examination

3. Ocular rationality tomography (oct) testing

4. Gonioscopy.

THE MANAGEMENT

When it comes to the treatment of steroid-induced ocular hypertension, the first thing that needs to be done is to immediately stop taking the medicine that was responsible for causing the problem. For the purpose of determining whether or not it is feasible to substitute systemic or inhaled steroids with an alternative therapy that does not involve the utilization of steroids, the cooperation of the patient's care team is an absolute necessity. When an ophthalmic steroid is the underlying cause of inflammation and/or macular edema, it is recommended to seek alternative treatments such as non-steroidal anti-inflammatory drugs (NSAIDs) and anti-VEGF medications. This is done in order to address the condition. For patients with glaucoma who are undergoing post-operative ocular steroid treatment, we advocate either the use of tapering topical steroids or the injection of a removable depot rather than an irremovable depot. Both of these options are available. In circumstances in which it is not possible to undertake withdrawal from topical steroids, it is vital to take into consideration the many different kinds of GC.

Medical management is the third paradigm of management to be discussed.

When it comes to SIG, beta-blockers are the medicine that is recommended the most frequently. Netarsudil, a drug that inhibits the formation of

stones, received clearance from the FDA in 2011. According to the evidence that has been presented, netarsudil has demonstrated a significant ability to reduce intraocular pressure (IOP) in patients with steroid-related glaucoma who are not responding to elective prescriptions. Anecortave acidic corrosive determination showed promising results in the management of SIG at some point between the years 2009 and 2012. The anecortave acidic corrosive determination does not have glucocorticoids development; it is obtained from cortisol. As far as we are aware, there has not been any additional late improvement that has been disseminated regarding the utilization of anecortave acidic corrosive inference for intraocular pressure. There are a number of studies that demonstrate that FML has a lower capacity to raise intraocular pressure in comparison to dexamethasone. This may be due to the fact that it has a limited visual vulnerability in comparison to other effective steroids.

trabeculoplasty with laser

Argon laser trabeculoplasty (ALT) and specific laser trabeculoplasty (SLT) are two procedures that are recommended for the administration of SIG in cases where antiglaucoma medications are not sufficient. SLT places a clear emphasis on the unregulated trabecular meshwork as its primary focus. In spite of the fact that it has the potential to cause intraocular aggravation, SLT has been shown to be effective in lowering intraocular pressure in eyes that have calm uveitis.

Surgery-based management

When patients do not exhibit any signs of progress while receiving clinical and laser treatments, it is recommended that they undergo cautious intervention. In a similar vein, it might be prudent for those who are most likely going to seek therapy with advanced steroids. When it comes to treating glaucoma that is brought on by the use of steroids, some of the careful options that are accessible include point-based surgery and trabecular diversion surgery. The trabeculectomy is the medical operation that is undertaken the majority of the time. Significant sclerectomy, canaloplasty, tube shunt surgeries, and cyclo-photocoagulation philosophy are some of the options that are available to patients.

DOCUMENTATION OF DIFFERENTIALS

It is of the utmost importance to ascertain whether the increase in intraocular pressure (IOP) that patients with POAG experience after receiving cautious dose is the result of a steroid-induced reaction. It is possible for individuals who use steroids but have not been diagnosed with glaucoma in the past to also have symptoms. When dealing with individuals who have uveitis glaucoma, determining the actual reason of raised intraocular pressure can be a difficult task, and in rare circumstances, it may even be impossible to accomplish. In addition to being treated with steroid medicine for an extended period of time, these eyes frequently have increased intraocular pressure as a result of a number of variables, including point conclusion, severe or persistent trabecular damage, and impaired trabecular outflow.

It can be difficult to draw a conclusion due to the fact that the degree of irritation in the front area cannot adequately reflect the degree of elevation in intraocular pressure, particularly in situations of trabeculitis. Patients who have uveitis glaucoma, which is characterized by a discontinuous drop in intraocular pressure (IOP) caused by a reduction in fluid production from the irritated ciliary body, have a more complicated clinical presentation than patients who do not have this condition. Another plausible mechanism could be responsible for the observed drop in intraocular pressure (IOP). One of these factors is uveoscleral outflow, which is facilitated by endogenous prostaglandins that are activated when irritation is present.

The presence of piercing and abrasive eye lesions in patients who have been treated with steroids may make it difficult to reach a judgment about the causes of the condition. A steroid-induced response may be observed in individuals who have taken drugs that have a rough visual surface. This is in addition to the raised intraocular pressure that is caused by widespread pain in the anterior chamber.

When doing a differential diagnosis and work-up for pediatric uveitic glaucoma, aphakic and pseudophakic pediatric glaucoma, or essential or optional intrinsic glaucoma, it is vital to take into consideration steroid-induced intraocular pressure (IOP) rise or glaucoma in children.

FINAL THOUGHTS

In the case of glaucoma improvement brought about by steroid medication, clinical mediation is the accountable party for the avoidable condition. The unsuitable and unique manner in which steroids are organized, particularly in developing nations, by local healthcare providers and by individuals who use them on their own, reveals a lack of awareness regarding the ailment. Through the implementation of a few essential safety procedures, it is possible to effectively prevent the commencement of SIG syndrome. Even though there have been significant breakthroughs in our understanding of the systems that cause corticosteroid-induced glaucoma in recent years, it is still necessary to conduct additional research. It is not uncommon for a comprehensive understanding of the reaction brought on by steroids to result in the development of novel therapeutic techniques for a variety of glaucoma types, including POAG.

REFERENCES

1. Feroze KB, Zeppieri M, Khazaeni L, [cited 2023 Dec 12].Steroid-InducedGlaucoma.TreasureIsland(FL):StatPearls Publishing;2023.
2. Kawahara A. A very early steroid responder after cataract surgery: acasereport.*BMCOphthalmol*.2023;23:237.
3. KerseyJP,BroadwayDC.Corticosteroid-inducedglaucoma:areviewoftheliterature.*Eye(Lond)*.2006;20(4):407–16.
4. Phulke S, Kaushik S, Kaur S, Pandav S.Steroid-induced Glaucoma:AnAvoidableIrreversibleBlindness. *JCurrGlaucomaPract*.2017;11(2):67–72.
5. FrancoisJ.Cortisoneandeyestrain.*AnnOcul(Pa ris)*.1954;187(9):805–16.
6. ClarkAF,WilsonK,MccartneyMD,MiggansST ,KunkleM,Howe W. Glucocorticoid-induced formation of cross-linked actin networksin cultured human trabecular meshwork cells. *Invest Ophthalmol VisSci*.1994;35(1):281–94.
7. YueBY.Theextracellularmatrixanditsmodulati oninthetrabecularmeshwork.*SurvOphthalmol*. 1996;40(5):379–90.
8. Jones RI, Rhee DJ.Corticosteroid-induced ocular hypertension andglaucoma: a brief review and update of the literature.*Curr OpinOphthalmol*.2006;17(2):163–7.
9. PleyerU,UrsellPG,RamaP.Intraocularpressure effectsofcommontopical steroids for post-cataract inflammation: are they all the same?*OphthalmolTher*.2013;2(2):55–72.
10. SheppardJD,ComstockTL,CavetME.Impactof theTopicalOphthalmicCorticosteroidLotepred nolEtabonateonIntraocularPressure.*AdvTher*.2 016;33(4):532–52.
11. Wijnants D, Stalmans I, Vandewalle E.The Effects of Intranasal,InhaledandSystemicGlucocorticoid sonIntraocularPressure:ALiteratureReview.*JC linMed*.2022;11(7):2007.
12. LebrizeS,ArnouldL,BourredjemA,BuschC,Re hakM,MassinP,etal.IntraocularPressureChang esAfterIntravitrealFluocinoloneAcetonideImp lant:ResultsfromFourEuropeanCountries.*Opht halmolTher*.2022;11(3):1217–29.
13. Armaly MF, Becker B.Intraocular pressure response to topicalcorticosteroids.*FedProc*.1965;24(6):12 74–8.
14. ArmalyMF.Effectofcorticosteroidsonintraocul arpressureandfluiddynamics. II. The effect of dexamethasone in the glaucomatous eye.*ArchOphthalmol*.1963;70:492–9.
15. NuyenB,WeinrebRN,RobbinsSL.Steroidinduc edglaucomainthepediatricpopulation.*JAAPOS*. 2017;21(1):1–6.